International Edition
Latest News
Health

UCLA Researchers Use CRISPR to Boost Healthy Genes in Autism Models

Lab-grown human brain cells can counteract the impact of an autism-linked genetic mutation by boosting the activity of a healthy gene copy, researchers at UCLA Health demonstrated in findings published in Nature Neuroscience. Autism carries a high heritability…

UCLA Researchers Use CRISPR to Boost Healthy Genes in Autism Models

Lab-grown human brain cells can counteract the impact of an autism-linked genetic mutation by boosting the activity of a healthy gene copy, researchers at UCLA Health demonstrated in findings published in Nature Neuroscience.

Autism carries a high heritability rate, with roughly 15% of its genetic risk originating from new mutations appearing for the first time in a child rather than coming from a parent. Many of these alterations disable one of the two copies of a gene.

A single working copy frequently fails to produce enough of the gene’s product independently, altering neurodevelopment. Conventional autism treatments primarily manage symptoms stemming from these genetic mutations instead of targeting the underlying biology.

Investigators led by Dr. Daniel Geschwind focused on two specific genes strongly linked to autism: CHD8 and SCN2A. CHD8 regulates other genes involved in brain development, while SCN2A enables neurons to fire electrical signals correctly.

Rather than editing or replacing the faulty gene, the team applied a modified version of CRISPR to alter the activity of the remaining healthy copy. They aimed this mechanism at enhancers, which are DNA stretches functioning like dials that control when and how strongly a gene is expressed.

“Many autism-linked mutations leave a person with one working copy of a gene instead of two,” said Dr. Daniel Geschwind, the Gordon and Virginia MacDonald distinguished professor of Human Genetics, Neurology and Psychiatry at UCLA.

“Our results show that, in human cell models, it’s possible to turn up that remaining copy and move cells back toward typical development. This is a key first step, and it gives us a new way to think about addressing the biology underlying these conditions.”

Boosting Healthy Genes Improves Organoid Growth and Neuron Activity

The research team evaluated the strategy across two distinct human stem cell-derived models: cultures of excitatory neurons and cortical organoids. These cortical organoids represent small clusters of brain-like tissue mimicking aspects of early brain development alongside key characteristics of neurodevelopmental disorders.

In the CHD8 models, boosting the healthy copy reduced abnormal organoid overgrowth, aided cellular maturation, and shifted gene activity toward typical levels. In the SCN2A models, the treatment restored substantial electrical activity in neurons, although some finer electrical properties normalized only in specific cell lines. The effect remained restricted to cells carrying the mutation, leaving healthy cells without increased gene activity and avoiding neighboring genes.

“What stands out to us is that the approach acted only in cell lines carrying the mutation and left healthy cell lines alone,” said George Chen, a former postdoctoral fellow in the Geschwind lab and current assistant professor of neurology at Children’s Hospital of Los Angeles. “That kind of specificity matters for any future therapy.”

Future Clinical Development Hurdles

Investigators emphasize that the work occurred entirely inside lab models, serving as a conceptual proof rather than an immediate treatment. The degree of gene expression shift varied among cell lines, and safe delivery to the human brain requires advanced methods and verification that the approach succeeds past the early developmental window.

Because the therapeutic strategy relies on utilizing a healthy gene copy, researchers expect the methodology to extend broadly to other neurodevelopmental conditions originating from a single faulty copy of a gene.

“We are still a long way from the clinic, and there is a lot of work ahead on delivery and timing, but these findings provide hope and give us a clear direction,” Chen said.

Frequently Asked Questions About the UCLA CRISPR Study

How does the modified CRISPR approach differ from traditional gene editing?

Traditional gene editing cuts or replaces faulty DNA sequences. This modified CRISPR technique instead targets regulatory DNA stretches called enhancers to turn up the activity of the remaining healthy gene copy without altering the genetic sequence itself.

What specific brain models did researchers use in the study?

The research team tested the technique on human stem cell-derived cultures of excitatory neurons and cortical organoids, which are small clusters of tissue designed to mimic early human brain development.

Will this method work for all types of autism cases?

The strategy specifically targets neurodevelopmental conditions caused by haploinsufficiency, where an individual has only one working copy of a gene instead of two. It does not apply to autism cases driven by other genetic mechanisms until further research establishes broader applications.

About the author: Dr Natalie Singh - Health Editor

Board‑certified internal‑medicine physician and MPH. Natalie authored peer‑reviewed studies on infectious disease and served as medical editor. “Dr. Natalie Singh delivers evidence‑based health news, medical breakthroughs, and expert wellness guidance.”